Effects of nonpeptide V(1) vasopressin receptor antagonist XXXX on @entity1188 volume and recovery of function in a focal @entity64 model.

@entity410 @entity64 @entity2657 @entity2806 @entity63 @entity2500 @entity548 @entity51 @entity1188 @entity432 @entity46463 @entity35 @entity717 @entity385
BACKGROUND AND PURPOSE: @entity2657 develops very early after the onset of focal @entity2806 and may be a major factor in @entity717 after an acute @entity385 . There have been very limited studies on the usefulness of antiedemic agents as neuroprotective agents in the setting of focal @entity2806 . We tested the neuroprotective effects of a new potent nonpeptide vasopressin receptor V(1) antagonist, @entity46463 , in a focal @entity64 model in @entity35 . METHODS: Focal @entity63 was induced by embolizing a preformed clot into the middle cerebral artery (MCA). @entity1188 volume was measured at 48 hours after the @entity2500 . @entity51 , @entity2657 , @entity410 activity, and mortality and @entity548 rates were also documented. RESULTS: Treatment with @entity46463 (2 mg/kg), initiated immediately after @entity2500 , significantly reduced @entity1188 volume (P<0.05) measured at 48 hours after the @entity432 . In animals in which the treatment was delayed for 1 hour after @entity2500 , @entity1188 volume was also reduced significantly (P<0.05). @entity1188 volume in the @entity35 that received the drug at 3 or 6 hours after @entity2500 was not different from that in the vehicle-treated group. Treatment with @entity46463 , when started early after the @entity432 , also reduced @entity51 and @entity2657 . Injection of drug at a higher dose (30 mg/kg) also reduced @entity1188 volume and improved functional recovery but was not superior to the lower dose (2 mg/kg) when the drug was administrated at 1 hour after @entity2500 . CONCLUSIONS: Our data show that the selective vasopressin receptor antagonist @entity46463 is a potent neuroprotective agent when used early after onset of @entity432 in an embolic focal @entity63 model in @entity35 . Further studies are needed in @entity64 models to better understand its neuroprotective properties when used alone or in combination with thrombolysis.
